Rothschild & Co Initiates Coverage On Apogee Therapeutics with Buy Rating, Announces Price Target of $140

Benzinga Newsdesk www.benzinga.com Positive 52.1%

Neg 0% Neu 0% Pos 52.1%

Rothschild & Co analyst Qize Ding initiates coverage on Apogee Therapeutics (NASDAQ:APGE) with a Buy rating and announces Price Target of $140.